Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Fludarabine phosphate

Fludarabine phosphate

pharmaceutical raw materials
Fludarabine phosphate structure

Fludarabine phosphate 

structure
  • CAS No:

    75607-67-9

  • Formula:

    C10H13FN5O7P

  • Chemical Name:

    Fludarabine phosphate

  • Synonyms:

    9H-Purin-6-amine,2-fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)-;2-Fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)-9H-purin-6-amine;Fludarabine phosphate;NSC 312887;NSC 328002;Fludara;Fludarabine 5′-monophosphate;2-Fluoroadenine arabinoside 5′-monophosphate;FAMP;Fludura;2-F-ara-AMP;Fludarabine 5′-dihydrogen phosphate

  • Categories:

    Active Pharmaceutical Ingredients  >  Antineoplastic Agents

Description

Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.


Solid


Fludarabine phosphate is a purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas. It has a role as an antimetabolite, an antineoplastic agent, an immunosuppressive agent, an antiviral agent, a prodrug and a DNA synthesis inhibitor. It is an organofluorine compound, a nucleoside analogue and a purine arabinonucleoside monophosphate. It derives from a 2-fluoroadenine.|Fludarabine Phosphate is the phosphate salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.

Fludarabine phosphate Basic Attributes

365.21

365.21

2017-001-1

1X9VK9O1SC

759194

DTXSID2023060

C1102

2934999090

Characteristics

186

-3.1

white Powder

2.4±0.1 g/cm3

203°C(dec.)(lit.)

864.2ºC at 760 mmHg

476.4±37.1 °C

1.879

soluble in DMSO or water at 5mg/ml;DMSO: soluble 1mg/mL

-20°C

(c = 0.5, H2O) [a]21D = 12 ± 2°

168.8 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

Safety Information

UN 2811 6.1/PG 3

3

R25:Toxic if swallowed.

S45

UO7440900

T

Bulk: Based on HPLC analysis, the sample is stable for at least one month when stored as the bulk chemical at room temperature and 60 °C. Solution: A 2 mg/mL aqueous solution is stable for at least 48 hours at room temperature and laboratory illumination (HPLC).

P201, P202, P260, P264, P270, P281, P308+P313, P314, P405, P501

H341

|Danger|H341 (97.53%): Suspected of causing genetic defects [Warning Germ cell mutagenicity]|P201, P202, P260, P264, P270, P281, P308+P313, P314, P405, and P501|Aggregated GHS information provided by 81 companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Drug Information

Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)|Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)

9 beta-D-arabinofuranosyl-2-fluoroadenine monophosphate

Fludarabine phosphate Use and Manufacturing

Methods of Manufacturing

Fludarabine (19. 5g ; 0.0683 moles) and (EtO) 3PO (79.1 ml; 0.465 moles) are introduced into a reactor cooled to-15/-20°C. POC13 (15.3 ml; 0.164 moles) is added dropwise over a period of approximately 1 hour while maintaining the internal temperature at - 10/-15°C. Agitation is maintained at-10/-15°C for 48 hours; the reaction is regarded as complete when the amount of fludarabine, in the HPLC area, is less than 2percent. Cold toluene (780 ml; 40 volumes) is then added over a period of approximately 1.5 hours and agitation is maintained, still at - 10/-15°C, for 1-2 hours. Filtration is carried out and the filter cake is washed with toluene (20 ml). The moist solid (approximately 35 g) is suspended in H20 (40 ml) and the pH is adjusted to 11 with 32percent NaOH (approximately 20 ml). The solution is percolated into a beaker containing Dowex resin [the resin must first be activated and washed as follows: washing is effected with demineralized water until the washing liquors are colourless; acidification with 5percent HCl (approximately 200 ml) is carried out and washing is effected to a neutral pH with demineralized water]. The whole is agitated for approximately 15 minutes and filtered over a septum. The resin is resuspended in H20 (500 ml). Agitation is carried out for 15 minutes followed by filtering over a septum. This operation is repeated until no more fludarabine phosphate is present in the filtrate. The fractions containing product are reduced in volume by evaporation under vacuum (at a maximum temperature of 30-35°C) until the desired product starts to precipitate, this product finally being filtered and dried under vacuum at 60°C to constant weight. 10. lg (40percent yield) of a white solid having a purity greater than 97.5percent are obtained. It is possible to recrystallize this solid as follows: it is suspended in 10 volumes of water and the whole is heated at 70°C for 1 hour; the whole is filtered hot, washing the filter cake with acetone. A white solid having a purity greater than 99percent is obtained.Fludarabine (10g), triethyl phosphate (90mL), phosphorus oxychloride (6mL) were placed under stirring -5~-10°C low temperature circulating pump, while maintaining the internal temperature -5 ~ -1 ° C; stirring reaction at -5 ~ -1 ° C for 15 hours; when the amount of fludarabine in the HPLC detection area, less than 2percent is considered The reaction was completed, then pure water (50 mL) was added to the obtained mixture under stirring, and washed with dichloromethane. The obtained aqueous phase was adjusted to pH=3 with 50percent NaOH solution, concentrated under reduced pressure at 35-40 ° C, and recrystallized. Filtration, the filter cake was washed with a small amount of ethanol and water to obtain a white solid. The white solid was dried under vacuum at 45-50 ° C for 10-12 hours to obtain a crude product of fludarabine phosphate having a purity of 99.2percent and a yield of 73.3percent.The crude fludarabine phosphate obtained by the above preparation method is added to 100 mL of pure water at room temperature, stirred uniformly, and 50percent NaOH solution is slowly added dropwise until completely dissolved, and the filtrate is added dropwise to a dilute hydrochloric acid solution at room temperature with a white solid. Precipitate, After suction filtration, the filter cake was washed with a small amount of ethanol and water to obtain a white solid. The white solid was vacuum-dried at 45-50 ° C for 10-12 hours to obtain fludarabine phosphate. The purity was 99.9percent, and the yield was 96.5. percent.To a 500 mL flask was added 20 g of fludarabine followed by 200 mL of triethyl phosphate, and the flask was placed at a low temperature of -6 ° CReaction bath, 20min after slowly dropping phosphorus oxychloride 20mL (side drop while stirring), the reaction 12 hours (TCL tracking). Reaction reachedTo the request after the flask quickly add 80mL water and 200mL dichloroethane, standing for 30 minutes after the extraction of water and organic phase, the waterAdjust the pH value to 2-3. Recrystallization white floc with a Buchner funnel filter, vacuum dry weighing a white powder20.71 g, yield 81.02percent, HPLC mass fraction 99.95percent,

Uses

anticonvulsant

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:365.21
XLogP3:-3.1
Hydrogen Bond Donor Count:5
Hydrogen Bond Acceptor Count:12
Rotatable Bond Count:4
Exact Mass:365.05366293
Monoisotopic Mass:365.05366293
Topological Polar Surface Area:186
Heavy Atom Count:24
Complexity:514
Defined Atom Stereocenter Count:4
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Drug Function and Efficacy

Extract from the above information

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • TAPI NL B.V.

    France France
    Active
  • Zhejiang Hisun Pharmaceutical Co., Ltd.

    China China
    Active
  • Shandong Newtime Pharmaceutical Co., Ltd.

    China China
    Active

Recommended Suppliers of Fludarabine phosphate

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.